Myelin-Oligodendrocyte Glycoprotein Antibody-associated Disease: Identifying Relapse Risk
PREDICTION of relapse in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has been achieved using a novel relapse risk score, according to data presented at the 18th World Congress on Controversies in Neurology (CONy), which took place in London, UK between the 21st–23rd March 2024.